525 results about "Antigenic peptide" patented technology

The invention relates to the technical field of biological information, in particular to an immunoreaction evaluation method based on tumor neoantigen activity sorting. The method comprises the following steps: obtaining genome data of tumor and normal tissues through whole exon sequencing, extracting multi-dimensional features of candidate somatic mutation, and screening by combining a Gaussian mixture model and a Transform model to obtain a high-confidence mutation genome set; predicting the HLA genotype of a patient based on sequencing data, translating and mutating into a peptide fragment, predicting the binding affinity of the peptide fragment and an MHC molecule by using an XGBoost model, and calculating a new antigen activity score sequence in combination with various parameters; and finally, synthesizing a new antigen peptide fragment according to a sorting result, carrying out in-vitro co-culture to detect an IFN-gamma secretion result, and dynamically optimizing a characteristic combination coefficient through a PPO algorithm to realize intelligent iterative updating, so that the accuracy of new antigen screening and the immunoreaction prediction capability are remarkably improved.

The invention relates to the field of biological medicines, in particular to a tumor antigen peptide and application thereof. The tumor antigen peptide provided by the invention comprises a peptide fragment with an amino acid sequence as shown in SEQ ID No.1. The tumor antigen peptide provided by the invention can be presented by the highest frequency HLA subtype (HLA-A * 11: 01) of Chinese population. In addition, through an in-vitro stimulation mode, it is verified that the tumor antigen peptide can effectively stimulate specific T cells, and a specific TCR element is successfully obtained. Therefore, a direct foundation is laid for further developing a TCR-T therapy, a therapeutic vaccine and other immunotherapies of the targeted human TP53R248Q.

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

The present application relates to the field of biomedicine, and in particular to a tumor antigen peptide and a use thereof. Provided is a tumor antigen peptide, comprising a peptide segment having an amino acid sequence as shown in SEQ ID NO: 1. The provided tumor antigen peptide can be presented by the HLA subtype (HLA-A*11:01) having a high proportion of Chinese population. Additionally, by means of in vitro stimulation, the tumor antigen peptide is verified to effectively stimulate specific T cells, and a specific TCR element is successfully obtained. The present application lays a direct foundation for further developing TCR-T therapy targeting human TP53 R248Q and immunotherapy such as therapeutic vaccines.

Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide / peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Provided are an antigenic peptide having multiple KRAS variant peptides linked thereto, mRNA encoding same, DNA encoding same, an immunogenic composition comprising an antigenic peptide having multiple KRAS variant peptides linked thereto or an mRNA encoding same, and a method for inducing an immune response to the KRAS variant peptides in a subject.

The invention discloses an HLA-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from an IDO1 gene. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The invention belongs to the technical field of biomedicine, and particularly relates to tumor neoantigen polypeptide based on EGFR gene mutation and application of the tumor neoantigen polypeptide. According to the effective method for predicting and screening the tumor neoantigen by using the tumor neoantigen prediction platform, the specific mutation of tumor tissues is obtained, and the neoantigen polypeptide with high immunogenicity, high affinity and high activation effect is more accurately predicted; the screened new antigen polypeptide makes up the blank of individualized antigen peptide in treatment of lung cancer NSCLC patients with EGFR-L858R somatic mutation, can be synthesized in a large scale, is used for subsequent standardized and individualized immunotherapy of EGFR-L858R mutation tumor patients, and has a good clinical application prospect.

The present invention provides a monkey serum amyloid A recombinant protein, a monoclonal antibody and a preparation method and application thereof, wherein the amino acid sequence of the recombinant protein is shown in SEQ ID No. 1, and the nucleotide sequence encoding the recombinant protein is shown in SEQ ID No. 2. By optimizing the antigen peptide sequence and the expression vector, the efficient and soluble expression of monkey serum amyloid A in Escherichia coli is achieved, and a mouse monoclonal antibody specifically binding to monkey serum amyloid A is screened based on the monkey serum amyloid A recombinant protein, and the above mouse monoclonal antibody is used to screen a pairable monoclonal antibody, and further based on the monoclonal antibody combination, a double antibody sandwich immune ELISA detection method or kit applied to monkey serum amyloid A recombinant protein is obtained, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The invention provides a tumor vaccine based on AKK bacteria and a preparation method and application thereof.Specifically, antigen peptide is subjected to lysine, on one hand, the free positive charge content of the antigen peptide is increased, the antigen peptide is endowed with the cell penetrating capacity, the two combined cell entering modes of direct cell penetrating and endocytosis are achieved, the cell entering number and rate of the antigen peptide are successfully increased, and the cell entering efficiency of the antigen peptide is improved; on the other hand, the modified peptide fragment and a bacterial adjuvant carrier are combined through simple stirring, and preparation and application of the tumor vaccine are successfully achieved. Therefore, the invention provides a simple, effective and universal tumor vaccine construction means, and provides a new thought for development and application of the cell-penetrating peptide.

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention provides a new antigen immunogenicity prediction method and system based on multi-feature fusion, and belongs to the technical field of machine learning, and the method comprises the steps: inputting a candidate peptide fragment sequence into an antigen intracellular processing prediction model to obtain a score representing the intracellular processing capability; inputting the candidate peptide fragment sequence into a pre-trained Transform model to obtain a sequence vector representation of the candidate peptide fragment; training an immunogenicity prediction model by taking the immunogenicity related characteristics, the sequence vector representation of the candidate peptide fragment and the score representing the intracellular processing capacity as a training sample; and screening the target candidate peptide fragment sequence by using the immunogenicity prediction model to obtain the tumor neoantigen. According to the method, the scoring model special for evaluating the intracellular processing and presentation capacity of the antigen peptide is constructed, the scoring model is output as a key feature, efficient fusion and learning are carried out on the key feature, multiple immunogenicity-related biological features and sequence vector representation of candidate peptide fragments, and the accuracy and reliability of tumor neoantigen immunogenicity prediction can be remarkably improved.

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention relates to the field of intelligent medical treatment, in particular to a new antigen screening method, equipment and a program product. Comprising the following steps: S1, acquiring tumor slice data and serum data of a patient; s2, performing data processing on the tumor slice data and the serum data to obtain an HLA / MHC pseudo sequence, antigen peptide data and an antigen gene expression level; the data processing comprises data sequencing, HLA / MHC typing, somatic mutation calculation, fusion gene calculation and gene expression profile calculation; s3, screening new antigens based on the HLA / MHC pseudo sequence, the antigen peptide data and the antigen gene expression level data to obtain the new antigens, the application can perform new antigen screening, and has good clinical value.

The invention discloses an HLA and antigen peptide combination prediction method based on interactive attention, and belongs to the technical field of computational biology. The method comprises the following steps: 1, collecting HLA allele and unique peptide fragment data, and constructing an HLA and antigen peptide binding data set; 2, constructing an HLA and antigen peptide binding prediction model, and training the prediction model by using the HLA and antigen peptide binding data set to obtain a trained prediction model; and step 3, inputting the HLA sequence and the antigen peptide sequence into the prediction model to obtain a prediction result of combination of the HLA and the antigen peptide. According to the method, prediction tasks based on a sequence and a structure are integrated into a unified model, and the potential of the pHLA about the sequence and the structure is analyzed and predicted. Compared with an existing method, the two-dimensional evaluation provides a more comprehensive antigen immunogenicity view angle, and a new insight is provided for the quality of a new antigen for triggering an immunoreaction.

The invention discloses an HLA (Human Leukocyte Antigen)-A * 11: 01 renal cell carcinoma tumor antigen short peptide derived from long-chain non-coding RNA (Ribonucleic Acid) LINC02717. The invention provides a tumor antigen peptide. The amino acid sequence of the tumor antigen peptide is as shown in SEQ ID No. 1. Researches find that a compound formed by the oligopeptide and a corresponding HLA molecule (HLA-A * 11: 01) can be recognized by T cells, and immune response is activated. The invention provides a potential target spot for treatment of renal cell carcinoma, and provides a new target spot screening direction for subsequent tumor antigen treatment of renal carcinoma.

The invention relates to the field of immunity, in particular to a T cell receptor with improved affinity, a nucleic acid molecule, a carrier, a cell and a medicine containing the T cell receptor, the nucleic acid molecule, the carrier and the cell for treating tumors. The T cell receptor includes a TCR [alpha] chain variable region and a TCR [beta] chain variable region, which have activity to bind to a KRAS G12V epitope and an HLA-A * 11 complex, and the TCR [alpha] chain variable region includes CDR1 [alpha], CDR2 [alpha] and CDR3 [alpha] complementarity determining regions, and the TCR [beta] chain variable region includes CDR1 [beta], CDR2 [beta] and CDR3 [beta] complementarity determining regions. The TCR provided by the invention has high-affinity target antigen peptide binding capacity, remarkably improves the target cell recognition capacity, shows good activation and killing activity, and shows high technical value and clinical application potential.

The invention belongs to the technical field of biological medicines, and particularly relates to an antigen peptide library for inducing tumor specific immune response, the antigen peptide library comprises eight antigen peptides, and the amino acid sequences of the eight antigen peptides are respectively shown as SEQ ID NO.1-SEQ ID NO.8. The invention further discloses a preparation method of the antigen peptide library. The antigen peptide has high immunogenicity and can effectively stimulate and induce generation of specific cytotoxic T lymphocytes when being loaded on antigen presenting cells, in-vitro killing experiments show that CTL cells induced and activated by loading new antigen DC have a high tumor killing effect, and the cell killing activity of the CTL cells is 90% or above. When model mice are treated by adoptive T cell back-transfusion of CTL cells induced by the new antigen peptide library, the tumor volume can be effectively reduced, the survival rate of the tumor can be remarkably increased, and good treatment potential is achieved.

The invention discloses an antigen peptide aiming at an anti-Ran K141Malunyl antibody and application thereof, the amino acid sequence of the antigen peptide is VFHR-(Malunyl) K-KNLQYY C, the (Malunyl) K represents malonylation modified lysine, the (Malunyl) K represents the amino acid sequence of the anti-Ran K141Malunyl antibody, and the (Malunyl) K represents the amino acid sequence of the anti-Ran K141Malunyl antibody. And the Ran K141Mallonyl represents that the 141 lysine of the Ran protein is subjected to malonylation modification. According to the present invention, the 141 site lysine malonylation modified polypeptide is artificially synthesized, the modified polypeptide is adopted as the antigen, the animal is immunized to prepare the specific antibody, and the antibody can be used for identifying the 141 site lysine malonylation of the Ran protein so as to be used in the development of the preparation of the prostate cancer diagnostic reagent.

The invention discloses application of a Lys35 site of a PC4 protein as a target spot in preparation of tumor diagnosis and treatment products. The invention provides application of a Lys35 site of a PC4 protein as a target spot in preparation of a tumor diagnosis product. The research shows that the Lys35 site methylation of the PC4 protein can promote the cell cycle progress of tumor cells and promote the proliferation growth and malignant progression of the tumor cells, and the scheme for inhibiting the site methylation can be used for developing tumor treatment drugs. Therefore, the Lys35 site of the PC4 protein can be used as a key target to be applied to development of tumor diagnosis products and targeted therapy drugs. The invention further develops the PC4 protein Lys35 methylation antigen peptide and the antibody capable of specifically recognizing the PC4 protein Lys35 methylation site, and the PC4 protein Lys35 methylation antigen peptide and the antibody can be applied to regulation and control of tumor cell proliferation or growth, can be used for developing diagnostic products and targeted therapy drugs for clinical tumor diseases, and have good clinical application value.

The present invention relates to an antigenic peptide targeting FLT3-D835 mutation and its application in tumor immunotherapy. Specifically, the present invention provides an antigenic peptide for eliciting an immune response targeting FLT3-D835 mutation. Compared with the lack of affinity between the wild-type polypeptide and HLA-A * 02:01 molecule, the antigenic peptide of the present invention has high affinity for HLA-A * 02:01 molecule. The present invention also provides the application of the antigenic peptide of the present invention. The antigenic peptide of the present invention has good immunogenicity, can activate specific immune responses, and has important clinical significance for targeting the clearance of leukemia cells, stabilizing the remission state of AML patients, and prolonging the disease-free survival time.

Provided are a vaccine for preventing feline herpesvirus infection, and a preparation method therefor and the use thereof. By means of antigen sequence design and screening, an antigen peptide and an mRNA nucleic acid molecule having excellent expression effects are obtained, and thus a vaccine prepared therefrom has a good immune effect and can induce the production of a highly-effective and durable level neutralizing antibody against a feline herpesvirus at a very low dose and dosing regimen; meanwhile, the mRNA vaccine has the characteristics of a good stability, a high delivery efficiency, safety, effectiveness and a controllable quality.

The invention discloses an African swine fever virus T cell epitope peptide for inducing swine T cell immune response and a composition of the African swine fever virus T cell epitope peptide. The amino acid sequence of the African swine fever virus T cell epitope peptide is shown as any one of SEQ ID NO.1-19. Or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1-19 and maintains the protein function shown in SEQ ID NO.1-19 through substitution and / or deletion and / or addition of one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1-19; the composition comprises amino acids of which the sequences are SEQ ID NO.1-19. A group of ASFV key T cell antigens and epitope peptides are obtained by combining IFN-gamma ELISpot and flow cytometry screening, the ASFV key T cell antigens and epitope peptides can be used as vaccine components to induce strong T cell immune response, and T cells activated by the antigen peptides have the maximum immune protection potential and are essential key antigens for ASFV vaccine research and development.

The invention relates to a universal hydrogel vaccine based on tumor neoantigen peptide as well as a preparation method and application of the universal hydrogel vaccine. The hydrogel vaccine comprises tumor neoantigen peptide hydrogel and an adjuvant loaded on the tumor neoantigen peptide hydrogel, the tumor neoantigen peptide-peptidyl assembly sequence conjugate is assembled in a solvent to form a nanofiber solution, and the nanofiber solution is triggered to form hydrogel under physiological conditions; the conjugate is obtained by coupling a tumor neoantigen peptide and a peptidyl assembly sequence through a covalent bond; the adjuvant is at least any one of a cell factor, an STING agonist, a Toll-like receptor agonist and an immune cell. The vaccine disclosed by the invention has universality, aiming at different tumor neoantigen peptides, self-assembly of a conjugate in a solvent is realized by regulating and controlling the quantity of valine or phenylalanine in a peptidyl assembly sequence to form a nanofiber solution, and the vaccine adjuvant is loaded through physical action to obtain a nanofiber solution containing the vaccine adjuvant; therefore, personalized cancer immunotherapy is realized.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides an antigen peptide which is different from a fragment of a human tumor antigen but has amino acid similarity to the fragment of the human tumor antigen. The invention also provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigen peptides and nucleic acids encoding such antigen peptides.

The invention provides a vaccine for preventing feline panleucopenia as well as a preparation method and application thereof. Through antigen sequence design and screening, the obtained antigen peptide and mRNA nucleic acid molecules have excellent expression effects, the prepared vaccine has a good immune effect, can induce generation of a strong and lasting horizontal neutralizing antibody aiming at the feline panleucopenia virus under a very low dosage and a very low administration scheme, and meanwhile, the vaccine can be used for preparing the feline panleucopenia virus vaccine for treating the feline panleucopenia virus. The mRNA vaccine provided by the invention has the characteristics of good stability, high delivery efficiency, safety, effectiveness and controllable quality.

The invention relates to the technical field of biological medicine, and provides a ginseng cell engineering tumor vaccine as well as a preparation method and application thereof. The ginseng cell engineering tumor vaccine comprises an exosome derived from a recombinant ginseng cell capable of expressing a tumor antigen; the recombinant ginseng cell capable of expressing the tumor antigen is obtained by introducing a recombinant plasmid containing tumor antigen DNA into a ginseng cell. According to the invention, ginseng cells in Chinese herbal medicines are taken as host cells for recombinant expression of tumor antigens, large-scale production of tumor vaccines can be realized through construction of an engineering recombinant cell system, biocompatibility and uniformity of the vaccines can be maintained, and safety risks can be reduced. Meanwhile, the prepared tumor antigen recombinant expression ginseng cell exosome can integrate the antigen, an adjuvant and a carrier, and the antigen phagocytosis, maturation and antigen peptide presentation capabilities of APCs are enhanced.